Tumor immune cycle analysis revealed significant differences in 16 steps between the high and low DDR1 expression groups of NSCLC patients (P < 0.05) (Figure 7D), with higher proliferation levels in the high-risk group. This evidence concerns the gene DDR1 and non-small cell lung carcinoma.